Interview: Why Europe’s Biotech ‘Prime Time’ Is Now

VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch

The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.   

Rocket
Sofinnova Plans 15 investments in the early-stage fund over three years • Source: Shutterstock

The chairman of Sofinnova Partners says “now is a prime time” to be investing in European biotech start-ups, as the region offers cutting edge science and technology, less frothy asset price tags, and a growing role to bridge commercial opportunities in the US and in China. 

Antoine Papiernik made the comments to Scrip when outlining the thinking behind Sofinnova’s latest funding round, completed October 18, which...

More from Financing

More from Business